Cargando…

HMPV in Immunocompromised Patients: Frequency and Severity in Pediatric Oncology Patients

Cancer is the first cause of death by disease in childhood globally. The most frequent types of cancers in children and adolescents are leukemias, followed by brain and central nervous system tumors and lymphomas. The recovery rate of cancer in children is around 80% in developed countries and up to...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Rodriguez, Cesar, Banos-Lara, Ma. del Rocio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168653/
https://www.ncbi.nlm.nih.gov/pubmed/31936721
http://dx.doi.org/10.3390/pathogens9010051
_version_ 1783523688286519296
author Martinez-Rodriguez, Cesar
Banos-Lara, Ma. del Rocio
author_facet Martinez-Rodriguez, Cesar
Banos-Lara, Ma. del Rocio
author_sort Martinez-Rodriguez, Cesar
collection PubMed
description Cancer is the first cause of death by disease in childhood globally. The most frequent types of cancers in children and adolescents are leukemias, followed by brain and central nervous system tumors and lymphomas. The recovery rate of cancer in children is around 80% in developed countries and up to 30% in developing countries. Some of the main causes of complications in children and adolescents with cancer are respiratory viral infections, mainly in bone marrow-transplanted patients. Respiratory viruses have been detected in the bronchoalveolar lavage or nasal wash specimens from cancer patients with or without respiratory illness symptoms. Human metapneumovirus (HMPV) is within the ten most common viruses that are encountered in samples from pediatric patients with underlying oncology conditions. In most of cases, HMPV is found as the only viral agent, but co-infection with other viruses or with bacterial agents has also been reported. The discrepancies between the most prevalent viral agents may be due to the different populations studied or the range of viral agents tested. Some of the cases of infection with HMPV in cancer patients have been fatal, especially in those who have received a hematopoietic stem cell transplant. This review seeks to show a general view of the participation of HMPV in respiratory illness as a complication of cancer in childhood and adolescence.
format Online
Article
Text
id pubmed-7168653
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71686532020-04-20 HMPV in Immunocompromised Patients: Frequency and Severity in Pediatric Oncology Patients Martinez-Rodriguez, Cesar Banos-Lara, Ma. del Rocio Pathogens Review Cancer is the first cause of death by disease in childhood globally. The most frequent types of cancers in children and adolescents are leukemias, followed by brain and central nervous system tumors and lymphomas. The recovery rate of cancer in children is around 80% in developed countries and up to 30% in developing countries. Some of the main causes of complications in children and adolescents with cancer are respiratory viral infections, mainly in bone marrow-transplanted patients. Respiratory viruses have been detected in the bronchoalveolar lavage or nasal wash specimens from cancer patients with or without respiratory illness symptoms. Human metapneumovirus (HMPV) is within the ten most common viruses that are encountered in samples from pediatric patients with underlying oncology conditions. In most of cases, HMPV is found as the only viral agent, but co-infection with other viruses or with bacterial agents has also been reported. The discrepancies between the most prevalent viral agents may be due to the different populations studied or the range of viral agents tested. Some of the cases of infection with HMPV in cancer patients have been fatal, especially in those who have received a hematopoietic stem cell transplant. This review seeks to show a general view of the participation of HMPV in respiratory illness as a complication of cancer in childhood and adolescence. MDPI 2020-01-10 /pmc/articles/PMC7168653/ /pubmed/31936721 http://dx.doi.org/10.3390/pathogens9010051 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Martinez-Rodriguez, Cesar
Banos-Lara, Ma. del Rocio
HMPV in Immunocompromised Patients: Frequency and Severity in Pediatric Oncology Patients
title HMPV in Immunocompromised Patients: Frequency and Severity in Pediatric Oncology Patients
title_full HMPV in Immunocompromised Patients: Frequency and Severity in Pediatric Oncology Patients
title_fullStr HMPV in Immunocompromised Patients: Frequency and Severity in Pediatric Oncology Patients
title_full_unstemmed HMPV in Immunocompromised Patients: Frequency and Severity in Pediatric Oncology Patients
title_short HMPV in Immunocompromised Patients: Frequency and Severity in Pediatric Oncology Patients
title_sort hmpv in immunocompromised patients: frequency and severity in pediatric oncology patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168653/
https://www.ncbi.nlm.nih.gov/pubmed/31936721
http://dx.doi.org/10.3390/pathogens9010051
work_keys_str_mv AT martinezrodriguezcesar hmpvinimmunocompromisedpatientsfrequencyandseverityinpediatriconcologypatients
AT banoslaramadelrocio hmpvinimmunocompromisedpatientsfrequencyandseverityinpediatriconcologypatients